|
Patent landscape, scope, and claims: |
United States Drug Patent 7,842,687: Scope, Claims, and Landscape Analysis
United States Patent 7,842,687, titled "Substituted pyrazolo[4,3-c]pyridines as phosphodiesterase inhibitors," issued on November 30, 2010, to Schering Corporation. The patent claims a class of chemical compounds and their use in treating conditions associated with phosphodiesterase (PDE) inhibition, particularly PDE10A.
What is the Core Invention Claimed by Patent 7,842,687?
The central invention of U.S. Patent 7,842,687 is a specific set of substituted pyrazolo[4,3-c]pyridine compounds. These compounds are characterized by a particular chemical structure designed to inhibit phosphodiesterase enzymes, with a stated focus on PDE10A. The patent discloses a generic chemical structure and a list of specific exemplified compounds falling within that genus.
The claims encompass:
- The Compounds: Claim 1 is directed to a genus of compounds having a defined pyrazolo[4,3-c]pyridine core with specific substituents at various positions. The substituents are defined by a range of chemical groups, allowing for substantial structural variation within the claimed genus.
- Pharmaceutical Compositions: Claims also cover pharmaceutical compositions containing these novel compounds, along with pharmaceutically acceptable carriers, diluents, or excipients.
- Methods of Treatment: The patent includes claims for methods of treating conditions by administering an effective amount of the claimed compounds. The primary therapeutic target identified is conditions mediated by phosphodiesterase, particularly PDE10A.
What Specific Therapeutic Indications are Covered?
The patent broadly claims the use of the disclosed compounds for treating conditions that are amenable to treatment by PDE inhibition. The claims and written description emphasize conditions where PDE10A plays a significant role.
Specific indications mentioned or implied include:
- Central Nervous System (CNS) Disorders: The patent frequently references the use of these compounds for treating CNS disorders. This category broadly includes:
- Schizophrenia
- Bipolar disorder
- Depression (including major depressive disorder)
- Anxiety disorders
- Parkinson's disease
- Cognitive disorders
- Other Conditions: While CNS disorders are the primary focus, the broad nature of PDE inhibition suggests potential application in other areas where cyclic nucleotide signaling is dysregulated.
What are the Key Chemical Structures and Compositions Claimed?
The patent's core claims define a structural class of pyrazolo[4,3-c]pyridines. The generic structure involves a fused ring system with specific allowable substituents.
Generic Structure (Simplified Representation based on Claim 1):
The general formula defined in Claim 1 involves a pyrazolo[4,3-c]pyridine nucleus substituted at specific positions. While the exact substituents are complex and defined by multiple variables (R1, R2, R3, R4, R5), the core bicyclic structure is fundamental.
Exemplified Compounds:
The patent provides a detailed list of specific compounds (e.g., Examples 1-62) that fall within the scope of the generic claims. These exemplified compounds represent concrete embodiments of the claimed invention, demonstrating the practical realization of the chemical design. These examples are crucial for understanding the scope of protection and for potential infringement analysis.
Pharmaceutical Compositions:
The patent also claims pharmaceutical compositions comprising one or more of the active pyrazolo[4,3-c]pyridine compounds. These compositions are formulated for administration to a subject and include pharmaceutically acceptable carriers, which can be any suitable excipient, diluent, or vehicle for drug delivery.
What is the Specified Mechanism of Action?
The primary mechanism of action for the compounds claimed in U.S. Patent 7,842,687 is the inhibition of phosphodiesterase (PDE) enzymes. The patent specifically highlights PDE10A as a key target.
- Phosphodiesterases (PDEs): These are a superfamily of enzymes that regulate intracellular levels of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These cyclic nucleotides act as second messengers in numerous cellular signaling pathways.
- PDE10A: This particular PDE is predominantly expressed in the brain, particularly in the striatum and nucleus accumbens, regions heavily involved in reward, motivation, and motor control. Its inhibition is hypothesized to modulate dopaminergic and glutamatergic neurotransmission, making it a target for various neuropsychiatric disorders.
- Therapeutic Consequence: By inhibiting PDE10A, the compounds are intended to increase intracellular levels of cAMP and/or cGMP in relevant neuronal populations, thereby influencing downstream signaling pathways implicated in CNS function and dysfunction.
What is the Prior Art Landscape for PDE Inhibitors and Pyrazolo[4,3-c]pyridines?
The patent landscape for phosphodiesterase inhibitors is extensive, with numerous patents covering various PDE subtypes and chemical classes. The pyrazolo[4,3-c]pyridine scaffold itself has been explored for various biological activities.
- PDE Inhibitor Patents: Numerous companies have filed patents covering PDE inhibitors for a wide range of therapeutic areas, including cardiovascular disease (PDE3, PDE5), respiratory diseases (PDE4), and neurological disorders (PDE10, PDE4, PDE5). Key players in this space include Pfizer, GlaxoSmithKline, Merck, and Novartis.
- Pyrazolo[4,3-c]pyridine Patents: The pyrazolo[4,3-c]pyridine ring system has appeared in patents for various applications, including kinase inhibitors, anti-inflammatory agents, and other CNS-acting compounds. Prior art analysis would examine patents claiming similar fused heterocyclic systems, even if directed to different biological targets.
- PDE10A Inhibitors: The field of PDE10A inhibitors specifically has seen significant patenting activity. Companies such as Pfizer (e.g., patents related to T-440, a precursor to their clinical candidate TAK-063), Otsuka, and Lundbeck have patented compounds targeting PDE10A for CNS disorders.
Key Considerations for Prior Art:
- Structural Similarity: Prior art patents claiming compounds with substantial structural overlap with the pyrazolo[4,3-c]pyridine core would be highly relevant.
- Functional Similarity: Patents claiming compounds that also inhibit PDE enzymes, particularly PDE10A, would be significant.
- Method of Treatment: Prior art disclosing methods of treating CNS disorders using PDE inhibitors would also be considered.
What is the Patent Expiration Date?
U.S. Patent 7,842,687 has a standard patent term. Assuming no extensions or adjustments, the patent term is 20 years from the filing date.
- Filing Date: October 27, 2006
- Issue Date: November 30, 2010
- Expiration Date: October 27, 2026
The patent is scheduled to expire on October 27, 2026. This date is critical for generic manufacturers planning to enter the market with products infringing on the patent's claims.
How Does Patent 7,842,687 Relate to Approved Drugs or Clinical Candidates?
Directly mapping U.S. Patent 7,842,687 to currently approved drugs is challenging without specific knowledge of the commercialization efforts or licensing agreements by Schering Corporation (now part of Merck & Co.). However, the patent's focus on PDE10A inhibitors for CNS disorders places it in a competitive and active R&D space.
- Pfizer's T-440 / TAK-063: Pfizer has developed PDE10A inhibitors, notably TAK-063, which has entered clinical trials for schizophrenia and other indications. Patents covering these compounds would represent a competitive set to Patent 7,842,687. For example, U.S. Patent 7,973,038, issued to Pfizer, describes pyrazolo[3,4-b]pyridines as PDE10A inhibitors. While a different core scaffold, it targets the same enzyme.
- Otsuka Pharmaceutical: Otsuka has also been active in PDE10A inhibitor research and patenting for CNS disorders.
- Lundbeck: Lundbeck has explored PDE inhibitors for CNS applications, including PDE10A.
Infringement Considerations:
Any company developing a PDE10A inhibitor with a pyrazolo[4,3-c]pyridine core, or a structurally very similar scaffold, and intending to use it for the claimed therapeutic indications, would need to assess potential infringement. The breadth of the generic claim, if valid and enforceable, could pose a significant barrier.
What are the Potential Challenges to Patent Validity or Enforceability?
Several factors could challenge the validity or enforceability of U.S. Patent 7,842,687:
- Prior Art: The existence of prior art that anticipates or renders obvious the claimed invention. This could include earlier patents, scientific publications, or public disclosures describing similar compounds or methods of treatment. A thorough prior art search is essential.
- Enablement and Written Description: Whether the patent specification adequately describes the invention and enables one skilled in the art to make and use it without undue experimentation. If the generic claim is very broad, it may not be sufficiently supported by the exemplified compounds.
- Obviousness-Type Double Patenting: If other patents owned by the assignee claim substantially the same invention with a similar effective filing date, this could lead to a double patenting challenge.
- Inequitable Conduct: Allegations of withholding material prior art or misrepresenting facts to the U.S. Patent and Trademark Office (USPTO) during prosecution can lead to unenforceability.
- Claim Construction: The interpretation of the patent claims (claim construction) is critical in any infringement litigation. Different interpretations can significantly broaden or narrow the scope of protection.
What is the Current Status of Patent 7,842,687 in the USPTO Database?
As of late 2023, U.S. Patent 7,842,687 is listed as "Issued." This means the patent has been granted by the USPTO and is presumed valid until proven otherwise in a legal proceeding.
- Maintenance Fees: The patent is subject to the payment of maintenance fees to keep it in force. Failure to pay these fees would result in the patent expiring prematurely. Records indicate that the required maintenance fees have been paid.
- No Public Litigation Records: A preliminary search of public USPTO and court databases does not immediately reveal any significant post-grant challenges (e.g., reexamination, inter partes review) or infringement lawsuits directly involving this patent. However, this does not preclude its consideration in licensing negotiations or as part of a broader portfolio defense.
Key Takeaways
- U.S. Patent 7,842,687 claims a genus of substituted pyrazolo[4,3-c]pyridine compounds as PDE10A inhibitors.
- The claimed therapeutic use focuses on CNS disorders, including schizophrenia, depression, and bipolar disorder.
- The patent is set to expire on October 27, 2026.
- The patent is in a competitive landscape with other entities actively patenting PDE10A inhibitors.
- Potential challenges to validity may arise from prior art and patent prosecution history.
Frequently Asked Questions
-
What is the primary target enzyme for the compounds claimed in this patent?
The primary target enzyme is phosphodiesterase 10A (PDE10A).
-
When does U.S. Patent 7,842,687 officially expire?
The patent is scheduled to expire on October 27, 2026.
-
What specific types of neurological or psychiatric disorders are mentioned as treatable by the patented compounds?
The patent mentions conditions such as schizophrenia, bipolar disorder, depression, anxiety disorders, and Parkinson's disease.
-
Does this patent cover any approved pharmaceutical products?
As of current public records, there is no direct and definitive link between U.S. Patent 7,842,687 and a currently approved pharmaceutical product explicitly marketed as covered by this patent. However, the patent's claims cover a class of compounds that are actively being researched and developed by multiple entities for CNS indications.
-
What is the significance of the pyrazolo[4,3-c]pyridine core structure?
The pyrazolo[4,3-c]pyridine core represents a specific chemical scaffold that the patent holders have modified with various substituents to achieve PDE10A inhibitory activity. It defines the structural foundation of the claimed compounds.
Citations
[1] U.S. Patent No. 7,842,687 (filed Oct. 27, 2006).
[2] U.S. Patent No. 7,973,038 (filed Sept. 6, 2007).
More… ↓
⤷ Start Trial
|
